TOC
Home > People at the DRFZ > PD Dr. med. Tobias Alexander

PD Dr. med. Tobias Alexander

Leader: Programme Area 4, PA 4 – Translational Rheumatology

Group leader: Autoimmunology

Liaison working group with Charité - Rheumatology and Clinical Immunology

+49 30 450 613137

tobias.alexander@charite.de

Scientific Background

2022
Completed postdoctoral dissertation (Habilitation, prerequisite for professorship) at the Humboldt University in Berlin

Since 2014
Consultant Rheumatologist, Head of Outpatient Clinic, Department of Rheumatology Charité – Universitätsmedizin Berlin, Germany

Since 2019
Group Leader German Rheumatism Research Centre Berlin, a Leibniz Institute, Autoimmunology Group

2010-2019
Postdoctoral position at Rheumatism Research Centre Berlin, a Leibniz Institute, Autoimmunology Group (Prof. Falk Hiepe)

2010
Degree thesis (Dr. med.), Faculty of Medicine, Humboldt University, Berlin)

2002-2010
Group member at Rheumatism Research Centre Berlin, a Leibniz Institute, Clinical Immunology (Prof. Andreas Thiel)

2014
Specialization in Rheumatology

2013
Specialization in Internal Medicine

2002-2013
Resident Department of Rheumatology, Charité – Universitätsmedizin Berlin, Germany

1995-2002
Study of Medicine, Humboldt-University Berlin, Germany

Since 2024
Chair of the Autoimmune Diseases Working Party (ADWP) of the EBMT

2016-2024
Secretary of the Autoimmune Diseases Working Party (ADWP) of the EBMT

Since 2017
Disease Coordinator for IgG4-RD of the ERN ReCONNET

Since 2017
Steering Committee Regionales Rheumazentrum Berlin

Since 2014
Steering Committee Deutsche Gesellschaft für Lupus-Forschung

2004-2007
Network Manager, N.I.R. supported by Federal Ministry of Economics

Member of DGRH, DGIM, Henry-Kunkel Society, Associated Editor Frontiers Immunology

Award Wolfgang-Schulze Foundation, EULAR-award of EWRR, Ideenwettbewerb Deutsche Rheumastiftung

Study support Janssen-Cilag 2022

TOP 5 PUBLICATIONS

Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, Knebel F, Burmester G, Radbruch A, Mei HE, Mashreghi MF, Hiepe F, Alexander T. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2020 Sep 17;383(12):1149-1155. doi: 10.1056/NEJMoa2023325
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015 Jul;74(7):1474-8. doi: 10.1136/annrheumdis-2014-206016.
γ-Secretase directly sheds the survival receptor BCMA from plasma cells Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rübsamen H, Wanngren J, Khademi M, Olsson T, Alexander T, Hiepe F, Pfister HW, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E. γ-secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015 Jun 11;6:7333. doi: 10.1038/ncomms8333.
Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus Alexander T, Krönke J, Cheng Q, Keller U, Krönke G. Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2024 Sep 5;391(9):864-866. doi: 10.1056/NEJMc2407150. PMID: 39231352

Autoimmunology

Alexander lab
learn more

News

Go to end of slider

Projects

Go to end of slider